Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01214174
(Study C11-01 started)
Proportion of Patients With Anterior Chamber Cell Clearing at Day 8 Post-Treatment [ Time Frame: 8 days post-treatment ]
This study will measure as its primary endpoint the anterior chamber cell count at Day 8 post-treatment in the study eye. The proportion of patients with anterior chamber cell count = 0 at Day 8 in the study eye for each dosage group will be compared. Only one eye was treated per participant.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.
Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
Patients with any signs of intraocular inflammation in either eye at screening.
Patients who have received any prior intravitreal injections in the study eye.